Furthermore, non-antioxidant, targeted protection against OS, including transition metal chelators, compounds that modify the oligomeric structure, and inhibitors of enzymatic ROS production (such an NADPH oxidase), may potentially exert a strong therapeutic effect against AD. This evidence concerns the gene FMO5 and Alzheimer disease.